Fig. 6From: Multiple criteria decision analysis in the context of health technology assessment: a simulation exercise on metastatic colorectal cancer with multiple stakeholders in the English settingCost benefit plot of overall weighted preference value (WPV) scores versus costs. Abbreviations: CET = cetuximab; PAN = Panitumumab; AFLI = Aflibercept (plus FOLFIRI). * Image produced using the M-MACBETH (beta) software version 3.0.0Back to article page